Key Takeaways:
- Medicare will cover GLP-1 weight loss drugs for $50/month starting July 1, 2026, through December 2027
- Eligible medications include all forms of Wegovy, Foundayo, and KwikPen Zepbound formulations
- This marks the first time Medicare has covered weight loss medications, affecting millions of beneficiaries
- The program serves as a bridge to a longer-term Medicare obesity treatment model starting in 2027
After decades of being locked out of weight loss treatment coverage, Medicare beneficiaries will gain access to certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027 under a groundbreaking new program announced this week by the Centers for Medicare & Medicaid Services (CMS).
The Medicare GLP-1 Bridge represents a seismic shift in how the nation's largest health insurance program approaches obesity treatment. It's a notable shift for Medicare, which has long been barred from covering weight loss treatments, and could provide relief to the estimated 40% of Medicare beneficiaries who struggle with obesity.
A Historic Break from Medicare's Weight Loss Ban
"These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost," said CMS Administrator Dr. Mehmet Oz. "The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible, while advancing our broader goal of helping Americans live healthier lives."
The timing couldn't be more critical. Even with discounts, current cash prices typically range from $149 to $699 per month. About half of GLP-1 users say these drugs were difficult for them to afford, according to KFF polling. A quarter said they were "very difficult" to afford.
For many Medicare beneficiaries who have watched younger Americans access these medications through employer insurance or private plans, this represents the first real opportunity to afford treatment. The program specifically addresses the coverage gap that has left millions of seniors unable to access medications like semaglutide injections and tirzepatide for weight management.
Under the new program, all formulations of Foundayo®, all formulations of Wegovy®, and the KwikPen® formulation of Zepbound® will be available to eligible beneficiaries through the Medicare GLP-1 Bridge. Notably, the single-dose vial and single-dose pen formulations of Zepbound® will not be available through the Medicare GLP-1 Bridge.
Who Qualifies and How to Access Coverage
Eligibility centers around body mass index (BMI) and health conditions. People will qualify if they have a body mass index of 27 or higher and have a condition such as heart disease or prediabetes, among others. People with BMIs of 35 or higher automatically qualify.
To get access to these weight loss medications, you must be enrolled in a Medicare Part D plan, which covers prescription drugs. However, this isn't your typical Part D benefit—CMS will be utilizing Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, as the central processor for the Medicare GLP-1 Bridge. The LI NET infrastructure provides the end-to-end operational capabilities and national scale that are critical to provide broad access to GLP-1 drugs to Medicare beneficiaries.
If you're already taking a GLP-1 medication for weight loss, you may still qualify for the Bridge program. Your prescriber will need to attest that you met the clinical criteria when you first started the medication. For example, if you started a GLP-1 in September 2024 with a BMI of 37, but in July 2026 you've lost weight and now have a BMI of 34, the prescriber should attest in the prior authorization request that you met the BMI criteria of 35 or over when the GLP-1 therapy started.
The Financial Reality for Medicare Beneficiaries
While $50 monthly represents substantial savings compared to retail prices exceeding $1,000, it may still present challenges for some Medicare beneficiaries living on fixed incomes.
If you receive the low-income subsidy, also known as the Medicare Extra Help program, you cannot use that assistance for the drugs covered by the GLP-1 Bridge program. For beneficiaries accustomed to paying a $5 or $10 copay for their pharmaceuticals, a $50 copay could still be a big financial barrier. "Fifty dollars a month sounds like a great deal compared to paying the discounted prices through TrumpRx and these other direct-to-consumer options, but it's a lot of money for somebody who's living on a $750-a-month Social Security check," said Juliette Cubanski, deputy director of the Program on Medicare Policy at KFF.
This cost consideration highlights why many beneficiaries have turned to alternative options while waiting for Medicare coverage. Some have explored telehealth providers offering competitive pricing, while others have sought out local clinics with patient assistance programs.
Bridge to the Future—But What Happens After 2027?
The Bridge will be a short-term demonstration that will run from July 1, 2026, to December 31, 2027. It will act as a transition to the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model, which starts in 2027.
However, the transition to long-term coverage isn't guaranteed. Within Medicare, if participation by Part D plan sponsors is less than the 80% threshold, CMS has stated that it will not launch the model in Medicare in 2027. This sets up the possibility that Medicare beneficiaries could have coverage of GLP-1s for obesity under the Medicare GLP-1 Bridge in the latter half of 2026 but then lose access in 2027 if the BALANCE model is not implemented.
This uncertainty means beneficiaries should prepare for potential coverage gaps. Understanding all available options—including private pay programs, manufacturer assistance, and alternative providers—remains important even with Medicare coverage on the horizon.
Preparing for the Program Launch
Healthcare providers and Medicare beneficiaries need to start preparing now for the July 1 launch. Providers will need to familiarize themselves with the new prior authorization process, which will run through Humana rather than individual Part D plans.
Beneficiaries should verify their Part D enrollment and discuss eligibility with their healthcare providers well before July. Documentation of BMI measurements and qualifying health conditions will be crucial for approval.
The program also represents an opportunity for healthcare systems to expand their obesity treatment programs, knowing that a significant portion of their Medicare population will soon have affordable access to these medications.
What This Means for You
If you're on Medicare and have been struggling with the cost of GLP-1 medications—or have avoided pursuing treatment due to cost concerns—this program could provide significant relief starting July 1, 2026. The $50 monthly cost represents savings of hundreds of dollars compared to current retail prices.
Start preparing now by discussing your eligibility with your doctor and ensuring you're enrolled in a Medicare Part D plan. Your healthcare provider will need to submit prior authorization requests through the new centralized system, not through your regular Part D plan.
For those seeking affordable GLP-1 treatment options before July 2026, compare costs across different providers and consider telehealth providers that offer competitive pricing. If you prefer in-person care, find a clinic near you that can help navigate both current options and prepare for the upcoming Medicare program.
This historic expansion of Medicare coverage represents more than cost savings—it signals a fundamental shift in how our healthcare system approaches obesity treatment for older Americans. While questions remain about long-term coverage beyond 2027, the Medicare GLP-1 Bridge offers an unprecedented opportunity for millions of beneficiaries to access life-changing treatment.
Sources
- Centers for Medicare & Medicaid Services - CMS announcement of $50 monthly GLP-1 access
- NPR - Medicare Bridge program analysis and beneficiary impact
- Medicare GLP-1 Bridge webpage - Official program details and eligibility requirements
- KFF analysis - BALANCE Model overview and potential challenges